Advertisement

Topics

Exelixis launches phase III trial for thyroid cancer drug, prompting outperform rating from Oppenheimer

08:07 EDT 8 Oct 2018 | Proactive Investors

The brokerage targets $40 a share for the stock, which is more than double the current share price of $17.27

Original Article: Exelixis launches phase III trial for thyroid cancer drug, prompting outperform rating from Oppenheimer

NEXT ARTICLE

More From BioPortfolio on "Exelixis launches phase III trial for thyroid cancer drug, prompting outperform rating from Oppenheimer"

Advertisement
Quick Search
Advertisement
Advertisement